Merck Beats On Q4 earnings, Anticipates Almost 80% Decline In COVID-19 Treatment Sales In 2023

  • Merck & Co Inc's MRK Q4 sales reached $13.8 billion, +2% Y/Y, beating the consensus of $13.67 billion. Excluding the foreign exchange impact, revenues were up 8%.
  • Pharmaceutical sales increased by 1% to $12.2 billion. Excluding the unfavorable impact of foreign exchange, pharmaceutical sales grew 9%, primarily driven by oncology and hospital acute care, partially offset by diabetes.
  • Growth in oncology was primarily driven by higher sales of Keytruda, which rose 19% to $5.5 billion.
  • Related: Merck, Pfizer Rebuts China's Request For Further Price Cuts For COVID-19 Drugs.
  • Vaccines sales performance reflects lower combined sales of Gardasil/ Gardasil 9 vaccines to prevent certain cancers and other diseases caused by HPV, which declined 4% to $1.47 billion.
  • Adjusted EPS of $1.62 also surpassed the analysts' estimate of $1.54 and declined 10% Y/Y.
  • Sales from COVID-19 treatment reached $825 million, down 13% Y/Y.
  • 2023 Guidance: Merck Anticipates FY23 sales of $57.2-$58.7 billion versus the consensus of $58.07 billion.
  • The company expects a significant decline in sales of Lagevrio (COVID-19 treatment), which are expected to be approximately $1.0 billion, down from $5.7 billion in 2022.
  • Merck expects adjusted EPS of $6.80-$6.95 versus the consensus of $7.36.
  • Price Action: MRK shares are down 1.20% at $105.70 during the premarket session on the last check Thursday.
Market News and Data brought to you by Benzinga APIs
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: BiotechEarningsLarge CapNewsGuidanceHealth CareMoversTrading IdeasGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!